Jefferies LLC

DRI Healthcare, the Canadian investment fund focused on pharmaceutical royalties, has postponed its $350m IPO on the London Stock Exchange, blaming the global equity market selloff caused by the spread of the Covid-19 virus.

Conditions are changing so fast with the coronavirus epidemic that each day could bring a change in sentiment, but for the time being leveraged finance is staying calm and continuing to function. There is more activity in this high risk corner of Europe’s capital markets than in any other, apart from sovereign, supranational and agency bonds.

The European Stability Mechanism has requested its primary dealers or ‘market group banks’ to set up entities within the 27 member states of the European Union in order for them to participate in bond auctions by the supranational and its sister issuer, the European Financial Stability Facility.

Barbeque-Nation Hospitality is planning an IPO of up to Rp12bn ($167.8m). It has revived its listing plans two years after first announcing the transaction.

Canada’s DRI Capital is preparing to list a new fund on the London Stock Exchange focused on investing in pharmaceuticals royalties.

A major shareholder in SLM Solutions Group, the German maker of 3D printers, sold a chunk of his stake in the company, via an accelerated bookbuild on Thursday.

Premier Oil has become the first company to announce a major ECM transaction in 2020, a £385m ($500m) capital increase to repay debt and finance the acquisition of two UK North Sea oilfields from BP.

I-Mab, a China-based biopharmaceutical company, has kicked off the roadshow for its up to $111.1m Nasdaq IPO, more than two months after filing draft documents with the US regulator.

The co-founders of Boohoo Group, the UK online fashion retailer, have offloaded £142.5m of stock.

Alphamab Oncology, a Chinese biopharmaceutical firm, has launched a roadshow for an up to HK$1.83bn ($233.8m) listing, according to a source close to the deal.

Alphamab Oncology, a Chinese biopharmaceutical company, kicked off pre-deal investor education for a potential $250m IPO on Monday after gaining approval to list from the Hong Kong Stock Exchange.

Chinese biopharmaceutical firm I-Mab has set the ball rolling for a potential $100m Nasdaq IPO, having filed a prospectus with the US regulator on Tuesday.